RxSight (RXST) Projected to Post Quarterly Earnings on Wednesday

RxSight (NASDAQ:RXST) will likely be issuing its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $29.7490 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

RxSight Trading Down 0.3%

RXST stock opened at $7.38 on Tuesday. The company has a market capitalization of $305.53 million, a P/E ratio of -7.77 and a beta of 1.24. RxSight has a twelve month low of $5.90 and a twelve month high of $16.74. The business has a 50 day simple moving average of $7.24 and a 200-day simple moving average of $8.96.

Analyst Upgrades and Downgrades

Several research firms have recently commented on RXST. UBS Group upped their price target on RxSight from $8.00 to $9.00 and gave the stock a “neutral” rating in a research note on Thursday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $13.00 price objective on shares of RxSight in a research note on Thursday, February 26th. Wolfe Research raised shares of RxSight to an “outperform” rating in a research note on Friday, January 30th. Stifel Nicolaus cut their price objective on shares of RxSight from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Monday, March 9th. Finally, William Blair started coverage on shares of RxSight in a research report on Friday, January 30th. They set a “market perform” rating for the company. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $9.78.

Hedge Funds Weigh In On RxSight

Large investors have recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in RxSight during the 2nd quarter worth $28,000. Caitong International Asset Management Co. Ltd raised its position in RxSight by 440.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock worth $39,000 after acquiring an additional 3,063 shares in the last quarter. Larson Financial Group LLC raised its position in RxSight by 110.5% in the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock worth $36,000 after acquiring an additional 2,089 shares in the last quarter. Tower Research Capital LLC TRC raised its position in RxSight by 156.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,574 shares of the company’s stock worth $72,000 after acquiring an additional 3,398 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its position in RxSight by 112.3% in the second quarter. Russell Investments Group Ltd. now owns 8,684 shares of the company’s stock worth $113,000 after acquiring an additional 4,593 shares in the last quarter. Hedge funds and other institutional investors own 78.78% of the company’s stock.

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.